Phosphorylated eIF2? predicts disease-free survival in triple-negative breast cancer patients.

ABSTRACT: Phosphorylated eukaryotic translation initiation factor 2? (p-eIF2?), which functions as a marker of endoplasmic reticulum stress, has been reported to be associated with patient prognosis in various cancers. However, little is known about the prognostic value of p-eIF2? in breast cancer, particularly in different breast cancer subtypes. An immunohistochemistry screen for p-eIF2? was performed using a tissue microarray containing 233 tumors and paired peritumoral tissues from female patients diagnosed with breast cancer. The staining results were scored semiquantitatively, and the p-eIF2? expression level in breast cancer and its potential prognostic value were investigated. In this retrospective cohort study, we found that p-eIF2? levels were significantly upregulated in breast cancer (P?

SUBMITTER: Guo L 

PROVIDER: S-EPMC5353635 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature